Quality-Adjusted Life Years (QALYS) for Inotuzumab Ozogamicin Versus Investigators Choice (IC) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia (R/R B-ALL)
Oct 1, 2017, 00:00 AM
10.1016/j.jval.2017.08.288
https://www.valueinhealthjournal.com/article/S1098-3015(17)30622-8/fulltext
Section Title :
Disease-Specific Studies
Section Order :
267
First Page :
A449
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30622-8&doi=10.1016/j.jval.2017.08.288